News | Atrial Fibrillation | May 15, 2019| Dave Fornell, Editor

Renal Artery Denervation and Catheter Ablation Increased Freedom From Atrial Fibrillation

The ERADICATE-AF Trial combined pulmonary vein isolation with renal denervation therapy

The ERADICATE-AF Trial combined pulmonary vein isolation with renal denervation therapy and showed imporve outcomes.

May 15, 2019 — Renal artery denervation (RDN) was found to be safe when employed with pulmonary vein isolation (PVI) to patients with paroxysmal atrial fibrillation (AF) and hypertension and significantly increased the likelihood of freedom from AF in a single-blind, randomized clinical trial. Results from the ERADICATE-AF Trial were presented during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Activation of the sympathetic nervous system plays an important role in the development and perpetuation of AFib. RDN can produce significant sympatholysis and a small randomized clinical trial has demonstrated enhanced efficacy when RDN is added to PVI for patients with AF and hypertension. The ERADICATE-AF Trial was designed to assess the safety and efficacy of RDN on long-term arrhythmic outcomes in a large single-blind longitudinal randomized clinical trial.

Patients with a history of hypertension (defined as SBP ≥ 130 and/or DBP ≥ 80 mmHg) despite ≥ one anti-hypertensive medication, and paroxysmal AF and plans for a guideline-supported catheter ablation, were eligible. Subjects were randomized 1:1 to PVI alone or PVI+RDN at five centers and were blinded to treatment assignment. Complete PVI was performed in all patients, and RDN by radiofrequency ablation catheters within each renal artery. The primary study endpoint was antiarrhythmic drug freedom from AF recurrence at 12 months (not including a three month blanking period). A sample size of 300 was calculated to provide 80% power to detect a relative 40% decrease in the one-year incidence of AF in patients treated with PVI+RDN compared to PVI alone.

The target sample size of randomized patients was met in March 2019 — age 60.2 ± 6.4 years, 40% female; baseline BP 150.2±8.7/89.8±8.9 mm Hg. Patients were well matched between groups. Periprocedural complications occurred in 13 (4.4%), not different between groups; all resolved prior to discharge. At the end of 12 months, the PVI+RDN group had significantly greater freedom of AF than the PVI only group: 71.4 vs 57.8 percent (HR = 0.61 [95%CI = 0.41-0.90], p = 0.011, Figure).

Additional prespecified secondary endpoints, including blood pressure control, will be analyzed in the future. The study results showed consideration of adjunctive RDN is reasonable to increase the success rate of AF ablation in patients with HTN.

All the HRS 2019 late-breaking studies 

Link to other HRS 2019 news



Related Content:

Medtronic Study Evaluating Combination of Pulmonary Vein Isolation, Renal Denervation for Atrial Fibrillation

VIDEO: New Approaches to Denervation Therapy 

Renal Artery Denervation and Catheter Ablation Increased Freedom From Atrial Fibrillation

VIDEO: Device Therapies to Treat Hypertension

SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation

Medtronic Announces Spyral HTN Global Clinical Trial Program for Renal Denervation

Medtronic Randomizes First Patients in Symplicity HTN-4

Medtronic Says its U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint

The Future of Renal Denervation Following the Failed SYMPLICITY HTN-3 Trial

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init